Vivos Therapeutics, Inc. (VVOS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VVOS SEC filings page.
Vivos Therapeutics, Inc. (VVOS) reported $20.9M in revenue over the twelve months to Jun 30, 2026, up 45.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business turns about 60% of sales into gross profit, but overhead and financing costs still drive substantial cash losses.
Revenue recovered in FY2025 while gross margin held near60% , yet the operating loss widened; this points to overhead, not product cost, as the main swing factor. Operating cash flow remained close to net loss in both years, while free cash flow was more negative after capital spending, so the losses broadly reflect cash consumption rather than mainly noncash charges.
Short-term liquidity deteriorated sharply in FY2025: current liabilities exceeded current assets, and the current ratio fell below 1.0x. Because total liabilities exceeded total assets, equity turned negative, leaving the reported capital structure reliant on liabilities and financing activity rather than positive book capital.
FY2025 financing inflow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Vivos Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Vivos Therapeutics, Inc. held $2.0M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $15.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Vivos Therapeutics, Inc. scores 7/100 among other emerging companies.
Vivos Therapeutics, Inc. had 13M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Vivos Therapeutics, Inc. scores 9/100 among other emerging companies.
Vivos Therapeutics, Inc. spent $100K on research and development in fiscal year 2025, which was 0.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Vivos Therapeutics, Inc. scores 5/100 among other emerging companies.
Vivos Therapeutics, Inc. reported revenue of $17.4M in fiscal year 2025, against $15.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Vivos Therapeutics, Inc. scores 59/100 among other emerging companies.
Vivos Therapeutics, Inc.'s operations used $15.3M of cash in fiscal year 2025, against $12.7M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Vivos Therapeutics, Inc. scores 35/100 among other emerging companies.
Vivos Therapeutics, Inc.'s cash, cash equivalents and investments came to $2.0M at the end of fiscal year 2025, against $26.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Vivos Therapeutics, Inc. scores 14/100 among other emerging companies.
Vivos Therapeutics, Inc. scores -9.49, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $125.4M against total assets of $25.2M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Vivos Therapeutics, Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Vivos Therapeutics, Inc. reported a net loss of $21.2M while operations used $15.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Vivos Therapeutics, Inc. reported an operating loss of $19.9M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Vivos Therapeutics, Inc. generated $5.2M in revenue in Q2 2026. This represents an increase of 34.9% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.
Vivos Therapeutics, Inc.'s EBITDA was -$4.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Vivos Therapeutics, Inc. reported a net loss of $5.5M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Vivos Therapeutics, Inc. earned -$0.31 per diluted share (EPS) in Q2 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Vivos Therapeutics, Inc. recorded an outflow of $3.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Vivos Therapeutics, Inc. held $1.8M in cash against $366K in long-term debt as of Q2 2026, with $20.4M of liabilities due within a year.
Not reported for Q2 2026.
Margins & Returns
Vivos Therapeutics, Inc.'s gross margin was 57.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.2 percentage points.
Vivos Therapeutics, Inc.'s operating margin was -93.6% in Q2 2026, reflecting core business profitability. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
Vivos Therapeutics, Inc. invested $416K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 46.0% from the same quarter a year earlier. Against the prior quarter it is up 2211.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
VVOS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M+34.9% | $5.1M+70.5% | $3.8M+3.4% | $6.8M+75.7% | $3.8M-5.8% | $3.0M-11.8% | $3.7M+13.9% | $3.9M+16.9% |
| Cost of Revenue | $2.2M+28.7% | $2.1M+38.2% | $838K-71.9% | $2.8M+86.5% | $1.7M+21.9% | $1.5M+1407.0% | $3.0Mn/m | $1.5M+1426.0% |
| Gross Profit | $3.0M+40.0% | $3.1M+102.7% | $3.0M+42.4% | $3.9M+68.7% | $2.1M-20.4% | $1.5M-22.1% | $2.1M+0.4% | $2.3M+33.6% |
| SG&A Expenses | $7.3M+9.0% | $9.2M+75.6% | $8.9M+87.5% | $8.3M+71.5% | $6.7M+50.1% | $5.3M-5.8% | $4.8M-21.7% | $4.8M-7.7% |
| Operating Income | -$4.8Mn/m | -$6.6Mn/m | -$6.4Mn/m | -$4.7Mn/m | -$4.9Mn/m | -$3.9Mn/m | -$2.8Mn/m | -$2.6Mn/m |
| EBITDA | -$4.3Mn/m | -$6.2Mn/m | -$5.9Mn/m | -$4.3Mn/m | -$4.6Mn/m | -$3.7Mn/m | -$2.7Mn/m | -$2.5Mn/m |
| Interest Expense | $1.1M | $1.1M | N/A | $500K | N/A | N/A | N/A | N/A |
| Net Income | -$5.5Mn/m | -$7.7Mn/m | -$6.9Mn/m | -$5.4Mn/m | -$5.0Mn/m | -$3.9Mn/m | -$2.8Mn/m | -$2.6Mn/m |
| EPS (Basic) | -$0.31 | -$0.52 | -$0.58 | -$0.49 | -$0.55 | -$0.45 | -$0.28 | -$0.40 |
| EPS (Diluted) | -$0.31 | -$0.52 | -$0.58 | -$0.49 | -$0.55 | -$0.45 | -$0.28 | -$0.40 |
| Diluted Shares (Avg) | 18M | 15M | N/A | 11M | 9M | 9M | N/A | 7M |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
VVOS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $24.1M-7.3% | $25.0M+122.0% | $25.2M+64.6% | $25.6M+67.1% | $26.0M+64.3% | $11.3M-4.4% | $15.3M+42.4% | $15.3M+48.8% |
| Current Assets | $4.2M-37.4% | $4.8M+33.6% | $4.4M-41.3% | $5.8M-21.8% | $6.7M-14.3% | $3.6M-0.1% | $7.5M+203.7% | $7.4M+272.7% |
| Cash & Equivalents | $1.8M-59.7% | $2.1M-9.9% | $2.0M-67.6% | $3.1M-51.1% | $4.4M-36.2% | $2.3M-10.3% | $6.3M+281.0% | $6.3M+538.8% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Accounts Receivable | $1.4M-11.9% | $1.8M+146.4% | $1.6M+267.7% | $2.1M+370.0% | $1.6M+313.4% | $718K+36.8% | $430K+112.9% | $454K+99.1% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $8.6M+1.4% | $8.6M+201.5% | $8.6M+201.5% | $8.4M+197.2% | $8.4M+197.2% | $2.8M0.0% | $2.8M0.0% | $2.8M0.0% |
| Total Liabilities | $28.1M+31.1% | $26.3M+282.7% | $26.7M+264.3% | $23.1M+200.9% | $21.4M+125.9% | $6.9M-38.7% | $7.3M-29.0% | $7.7M-25.2% |
| Current Liabilities | $20.4M+217.3% | $17.9M+281.6% | $18.1M+263.1% | $7.4M+45.1% | $6.4M-3.3% | $4.7M-41.7% | $5.0M-31.7% | $5.1M-28.5% |
| Non-Current Liabilities | $7.7M-48.5% | $8.4M+285.1% | $8.6M+266.8% | $15.7M+513.3% | $15.0M+426.8% | $2.2M-31.0% | $2.4M-22.4% | $2.6M-17.7% |
| Long-Term Debt | $366K-95.3% | $418K | $469K-60.9% | $8.4M+598.3% | $7.8M+546.7% | N/A | $1.2M0.0% | $1.2M0.0% |
| Total Equity | -$3.8M-183.2% | -$1.1M-125.8% | -$1.5M-118.7% | $2.5M-67.0% | $4.6M-27.8% | $4.4M+657.2% | $8.0M+1835.3% | $7.7M+16563.0% |
| Retained Earnings | -$138.5Mn/m | -$133.0Mn/m | -$125.4Mn/m | -$118.5Mn/m | -$113.1Mn/m | -$108.1Mn/m | -$104.2Mn/m | -$101.4Mn/m |
Not reported in any period shown, so not listed: Inventory.
VVOS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.1Mn/m | -$6.0Mn/m | -$3.8Mn/m | -$4.2Mn/m | -$3.5Mn/m | -$3.8Mn/m | -$2.9Mn/m | -$4.2Mn/m |
| Depreciation & Amortization | $510K+66.7% | $454K+156.5% | $442K+206.9% | $384K+163.0% | $306K+111.0% | $177K+21.2% | $144K-3.4% | $146K-2.7% |
| Stock-Based Compensation | $100K-66.7% | $151K-52.4% | N/A | $100K0.0% | $300K-50.0% | $317K+8.2% | N/A | $100K-50.0% |
| Capital Expenditures | $416K-46.0% | $18K-85.2% | $1.5M+827.9% | -$83K-56.8% | $771K+1185.0% | $122K-19.2% | $165K0.0% | $192K+24.7% |
| Free Cash Flow | -$3.6Mn/m | -$6.0Mn/m | -$5.3Mn/m | -$4.2Mn/m | -$4.3Mn/m | -$3.9Mn/m | -$3.1Mn/m | -$4.4Mn/m |
| Investing Cash Flow | -$416Kn/m | -$18Kn/m | -$1.6Mn/m | $83Kn/m | -$5.9Mn/m | -$122Kn/m | -$165Kn/m | -$192Kn/m |
| Financing Cash Flow | $3.2M | $6.1M | $4.3M+41.9% | $2.8M-27.0% | N/A | N/A | $3.1M-14.4% | $3.8Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VVOS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.3%+2.1pp | 59.5%+9.5pp | 78.1%+21.4pp | 58.0%-2.4pp | 55.2%-10.2pp | 50.0%-6.6pp | 56.7%-7.6pp | 60.5%+7.6pp |
| Operating Margin | -93.6% | -128.7% | -166.8% | -69.8%-1.3pp | -127.4% | -129.9% | -75.8% | -68.5% |
| Net Margin | -106.4% | -149.4% | -180.3% | -79.6%-11.8pp | -131.2% | -128.1% | -76.4% | -67.8%-4.4pp |
| Return on Equity | N/A | N/A | N/A | -213.3%-179.1pp | -109.4%-79.0pp | -87.7%+558.9pp | -35.5%+1000.7pp | -34.1%+4515.9pp |
| Return on Assets | -22.7%-3.4pp | -30.7%+3.6pp | -27.4%-8.9pp | -21.1%-4.0pp | -19.3%-7.1pp | -34.3%-2.4pp | -18.5%+21.2pp | -17.1%+3.2pp |
| Current Ratio | 0.21-0.8x | 0.27-0.5x | 0.24-1.3x | 0.78-0.7x | 1.05-0.1x | 0.77+0.3x | 1.50+1.2x | 1.44+1.2x |
| Debt-to-Equity | N/A | N/A | N/A | 3.31+3.2x | 1.69+1.5x | N/A | 0.15-2.8x | 0.16-25.9x |
| Liabilities-to-Equity | N/A | N/A | N/A | 9.13+8.1x | 4.68+3.2x | 1.56-17.7x | 0.92-24.2x | 1.00-222.3x |
| Asset Turnover | 0.21+0.1x | 0.21-0.1x | 0.15-0.1x | 0.260.0x | 0.15-0.1x | 0.270.0x | 0.24-0.1x | 0.25-0.1x |
| FCF Margin | -69.2% | -117.3% | -139.7% | -62.6% | -111.7% | -129.9% | -84.0%+5.7pp | -113.5% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$1.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.24), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Vivos Therapeutics, Inc. VVOS | FY2025 | $17.4M | -$21.2M | N/A | $2.7M | 22/100 |
| Adagio Medical Holdings, Inc ADGM | FY2025 | $0 | -$25.1M | N/A | $2.8M | — |
| Nortech Systems Inc NSYS | FY2025 | $118.4M | -$252K | -0.2% | $29.4M | 36/100 |
| Envoy Medical, Inc. COCH | FY2025 | $241K | -$23.8M | N/A | $46.1M | — |
| Myomo Inc. MYO | FY2025 | $40.9M | -$15.6M | -38.0% | $47.9M | 45/100 |
| Iridex Corp IRIX | FY2025 | $52.7M | -$4.4M | -8.4% | $13.1M | 52/100 |
Where Vivos Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Vivos Therapeutics, Inc.'s annual revenue?
Vivos Therapeutics, Inc. (VVOS) reported $17.4M in total revenue for fiscal year 2025. This represents a 16.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Vivos Therapeutics, Inc.'s revenue growing?
Vivos Therapeutics, Inc. (VVOS) revenue grew by 16.0% year-over-year, from $15.0M to $17.4M in fiscal year 2025.
Is Vivos Therapeutics, Inc. profitable?
No, Vivos Therapeutics, Inc. (VVOS) reported a net loss of $25.5M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $21.2M.
What is Vivos Therapeutics, Inc.'s EBITDA?
Vivos Therapeutics, Inc. (VVOS) had EBITDA of -$18.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Vivos Therapeutics, Inc. have?
As of fiscal year 2025, Vivos Therapeutics, Inc. (VVOS) had $2.0M in cash and equivalents against $469K in long-term debt.
What is Vivos Therapeutics, Inc.'s gross margin?
Vivos Therapeutics, Inc. (VVOS) had a gross margin of 60.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Vivos Therapeutics, Inc.'s free cash flow?
Vivos Therapeutics, Inc. (VVOS) recorded an outflow of $17.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Vivos Therapeutics, Inc.'s operating cash flow?
Vivos Therapeutics, Inc. (VVOS) recorded an outflow of $15.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Vivos Therapeutics, Inc.'s total assets?
Vivos Therapeutics, Inc. (VVOS) had $25.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Vivos Therapeutics, Inc.'s capital expenditures?
Vivos Therapeutics, Inc. (VVOS) invested $2.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Vivos Therapeutics, Inc. spend on research and development?
Vivos Therapeutics, Inc. (VVOS) invested $100K in research and development during fiscal year 2025.
What is Vivos Therapeutics, Inc.'s current ratio?
Vivos Therapeutics, Inc. (VVOS) had a current ratio of 0.24 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Vivos Therapeutics, Inc.'s return on assets (ROA)?
Vivos Therapeutics, Inc. (VVOS) had a return on assets of -84.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Vivos Therapeutics, Inc.'s P/E ratio?
Vivos Therapeutics, Inc. (VVOS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.7M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Vivos Therapeutics, Inc.'s price-to-sales ratio?
Vivos Therapeutics, Inc. (VVOS) trades at 0.1x sales, its market capitalization divided by $20.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.7M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Vivos Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Vivos Therapeutics, Inc. (VVOS) held $2.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $15.3M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Vivos Therapeutics, Inc.'s debt-to-equity ratio negative or not reported?
Vivos Therapeutics, Inc. (VVOS) has negative shareholder equity of -$1.5M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Vivos Therapeutics, Inc.'s Altman Z-Score?
Vivos Therapeutics, Inc. (VVOS) has an Altman Z-Score of -9.49, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Vivos Therapeutics, Inc.'s Piotroski F-Score?
Vivos Therapeutics, Inc. (VVOS) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Vivos Therapeutics, Inc.'s earnings high quality?
Vivos Therapeutics, Inc. (VVOS) reported a net loss of $21.2M while operations used $15.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Vivos Therapeutics, Inc. cover its interest payments?
Vivos Therapeutics, Inc. (VVOS) reported an operating loss of $19.9M against $1.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Vivos Therapeutics, Inc.?
Vivos Therapeutics, Inc. (VVOS) scores 22 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.